Plexxikon Inc.

Splunk Inc.

Kairoi Healthcare Strategies, Inc.

Cisco Technology, Inc.

University of California

Opna Immuno-oncology Sa

Jeffrey Yung Wu

Wayne Spevak

Guoxian Wu

Jiazhong Zhang

Songyuan Shi

Phuongly Pham

John Buell

Prabha N Ibrahim

Jack Lin

Ying Zhang

Katrina Chan

Nathaniel Gerard McKervey

Ryan Russell Moore

Stephen Robert Luedtke

Aaron Edward Albers

Zuojun Guo

Hannah Powers

Russell D Lee

Chao Zhang

Todd Ewing

F Dean Toste

Gregory Hamilton

Hiroaki Inagaki

Jack Walleshauser

Elizabeth A Burton

Ken Dong

Takashi Honjo

Yongil Jin

Vivek Rauniyar

Aaron D Lackner

Robert J Phipps

Hunter Shunatona

Natalja Frueh

Yiming Wang

Jigar Patel

Systems and methods are described to correlate different types of data obtained from a distributed ledger system. The distributed ledger system can generate transaction notifications, log data, and/or metrics data. At least some of the data generated by the distributed ledger system can be obtained by a data intake and query system via a distributed ledger system monitor. The data from the distributed ledger system can be stored in the data intake and query system and correlated. Based on the correlation, the data intake and query system can determine a history of a transaction in the distributed ledger system, relationships between components of the distributed ledger system, and/or an architecture of the distributed ledger system.

Correlating different types of data of a distributed ledger system

Systems and methods are described to associate data from different nodes of a distributed ledger system. The nodes can generate transaction notifications, log data, and/or metrics data. At least some of the data generated by the nodes can be obtained by a data intake and query system via a distributed ledger system monitor. The data from the distributed ledger system can be stored in the data intake and query system and correlated. Based on an association between at least some of the data of the first node and at least some of the data of the second node, the data intake and query system can determine at least a partial history of a transaction in the distributed ledger system, relationships between components of the distributed ledger system, and/or an architecture of the distributed ledger system.

Associating data from different nodes of a distributed ledger system

Compounds and methods for EP300 or CBP modulation and indications therefor

Compounds and methods for CDK8 modulation and indications therefor

Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Heterocyclic compounds and uses thereof

A scheduling system and method for data cleansing may be used to optimize clinical scheduling. The present disclosure describes receiving clinical record data, in an agnostic manner, from a system including a source scheduling database containing the clinical record data; mapping the clinical record data to a desired format; conforming the clinical record data to standardized scheduling elements of the scheduling system; cleansing, in a manner configurable by a user, the clinical record data to purge portions of the clinical record data; providing the clinical record data to an optimization engine for optimization of the clinical record data; optimizing the clinical record data by applying configurable logic to the clinical record data; and uploading one or more newly defined optimized scheduling templates via an outbound connection back to the scheduling system.

Systems and methods for data cleansing such as for optimizing clinical scheduling

Disclosed are compounds of Formula I(b): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R, R, R, each R, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Compounds and methods for kinase modulation, and indications therefor

The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reagents has enabled a vast set of enantioselective transformations. A largely overlooked analogous mechanism wherein a chiral anionic catalyst brings a cationic species into solution is itself a powerful method. The concept is broadly applicable to a number of different reaction pathways, including to the enantioselective fluorocyclization of olefins, and dearomatization of aromatic systems with a cationic electrophile-transferring (e.g., fluorinating) agent and a chiral phosphate catalyst. The reactions proceed in high yield and stereoselectivity. The compounds and methods of the invention are of particular value, especially considering the scarcity of alternative approaches.

Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst

Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z, Z, and Zare as described herein, compositions thereof, and uses thereof.

Growing community of inventors

Berkeley, CA, United States of America

Jeffrey Yung Wu